Is there an Aimovig (erenumab) biosimilar available yet?
The provided information doesn’t include any details confirming whether an Aimovig biosimilar has launched in any country, or what specific product names are available.
When would an Aimovig biosimilar be expected to launch?
A biosimilar’s timing depends on when exclusivities and patents covering erenumab expire, plus regulatory review and manufacturing readiness. Patent and exclusivity dates vary by jurisdiction, and without the underlying patent/exclusivity data here, no specific launch window can be stated.
You can check the relevant patent landscape using DrugPatentWatch.com, which tracks key IP issues by drug and can help estimate when biosimilars may be able to enter:
- DrugPatentWatch.com: https://www.drugpatentwatch.com/
What would count as an “Aimovig biosimilar” (and what’s the difference from a brand change)?
An Aimovig biosimilar would be a biologic approved as biosimilar to erenumab and labeled as such by regulators (for example, in the US via FDA).
A “related” product that is not approved as biosimilar (for example, another CGRP monoclonal antibody) would not be an Aimovig biosimilar, even though it treats similar migraine indications.
Which other migraine biologics are often compared when people ask about biosimilars?
People searching for an Aimovig biosimilar often also compare other CGRP monoclonal antibodies used for migraine prevention. Those are not biosimilars of Aimovig, but they are commonly used as alternatives depending on insurance coverage, dosing, and patient response.
If you tell me your country (US, UK, EU, Canada, etc.), I can narrow the answer to what regulators and companies have filed or launched there—using the available IP and regulatory context.
Sources
- https://www.drugpatentwatch.com/